<DOC>
	<DOCNO>NCT01933906</DOCNO>
	<brief_summary>In phase I pilot study , plan investigate feasibility safety add interferon therapy preexist imatinib treatment patient chronic phase chronic myeloid leukaemia . The participate patient already reach response imatinib therapy ( CCyR ) still detectable disease ( molecular response MR 4.5 better ) .</brief_summary>
	<brief_title>Addition P1101 Imatinib Treatment Patients With Chronic Phase Chronic Myeloid Leukaemia Not Achieving Complete Molecular Response</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>Patients ≥ 18 year age BCRABL positive chronic myeloid leukaemia chronic phase treat imatinib first line therapy CHR , CCyR least 18 month imatinib treatment Adequate organ function , define follow : total bilirubin &lt; 1.5 x ULN , AST ALT &lt; 2.5 x ULN , creatinine &lt; 1.5 x ULN , ANC &gt; 1.5 x 109/L , platelet &gt; 100 x 109/L Written , voluntarily sign informed consent CMR ( molecular remission 4.5 BCRABL transcript undetectable ) Patient receive investigational treatment within 28 day study entry Treatment second generation tyrosine kinase inhibitor ( dasatinib , nilotinib ) ECOG performance status ≥ 3 Patients primary different histological origin study indication ( unless relapsefree interval ≥ 5 year , except cervical carcinoma , basal cell epithelioma squamous cell carcinoma skin ) Evidence severe uncontrolled systemic disease ( e.g . unstable uncompensated respiratory , cardiac , hepatic renal disease etc . ) Acute chronic infection Known autoimmune disease ( e.g . collagen disease , polyarthritis , immune thrombocytopenia , thyroiditis , psoriasis , lupus nephritis autoimmune disorder ) Female patient pregnant breastfeed Known diagnosis HIV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>CML</keyword>
	<keyword>Chronic myeloid leukemia</keyword>
	<keyword>Chronic myeloid leukaemia</keyword>
	<keyword>PEG-Proline-Interferon-alpha 2b</keyword>
	<keyword>Interferon</keyword>
	<keyword>P1101</keyword>
	<keyword>Imatinib</keyword>
</DOC>